Effect of Diabetes Mellitus on Sepsis Induced Multiple Organ Dysfunction Syndrome By Hayes Brown.

Effect of Diabetes Mellitus on Sepsis Induced Multiple

Organ Dysfunction Syndrome

By Hayes BrownBy Hayes Brown

NeedNeed

Each year 500,000 people develop Each year 500,000 people develop sepsis, with a survival rate of 29 sepsis, with a survival rate of 29 percentpercent

Millions are spent on patient safety Millions are spent on patient safety researchresearch

250,000 die each year in the United 250,000 die each year in the United statesstates

Knowledge BaseKnowledge Base

CytokineCytokine

Diabetes MellitusDiabetes Mellitus

Death in women from diabetes

Type 1 and Type 2Type 1 and Type 2

DM and SepsisDM and Sepsis

Knowledge BaseKnowledge Base

Studies could help determine the Studies could help determine the relationship of DM and reduced risk relationship of DM and reduced risk of ALIof ALI

Suggested ReasonsSuggested Reasons

Hospitalized EarlierHospitalized Earlier Red blood cell deformability Red blood cell deformability

increases risk of renal failureincreases risk of renal failure Diabetics more vulnerable to Diabetics more vulnerable to

bacteremiabacteremia

Literature ReviewLiterature Review

Dr Tomsen (2008)-heightened risk of Dr Tomsen (2008)-heightened risk of infections in diabetic peopleinfections in diabetic people

Dr. Reimar(2007)-patients with bacteremia Dr. Reimar(2007)-patients with bacteremia caused by caused by E. E. coli and related bacteria found coli and related bacteria found about 17 percent had diabetes, compared about 17 percent had diabetes, compared with 6% without diabeteswith 6% without diabetes

Dr. Friedman(2005)- DM Dr. Friedman(2005)- DM

patients have a greaterpatients have a greater

risk of renal failure due risk of renal failure due

to red blood cell deformibilityto red blood cell deformibility

Literature ReviewLiterature Review Dr. Annette Esper (2006)-patients with Dr. Annette Esper (2006)-patients with

Diabetes Mellitus less likely to develop Diabetes Mellitus less likely to develop respiratory failure during periods of sepsis, respiratory failure during periods of sepsis, but more likely to develop infection of the but more likely to develop infection of the urinary system urinary system

Dr. Martin- those with (2006)Dr. Martin- those with (2006)

DM less likely to develop DM less likely to develop

respiratory infection because respiratory infection because

DM patients may beDM patients may be

hospitalized earlier hospitalized earlier

BibliographyBibliography ^̂ Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS,

Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001-03-08). "Recombinant human protein C Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001-03-08). "Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis recombinant human activated protein C for severe sepsis

Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (Apr 2003). "2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Ramsay G (Apr 2003). "2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference Conference

Meduri GU, Golden E, Freire AX, et al (Apr 2007). "Methylprednisolone infusion in early severe Meduri GU, Golden E, Freire AX, et al (Apr 2007). "Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial ARDS: results of a randomized controlled trial

http://www.nlm.nih.gov/medlineplus/ency/article/000666.htm http://www.nlm.nih.gov/medlineplus/ency/article/000666.htm http://my.clevelandclinic.org/disorders/sepsis/hic_sepsis.aspxhttp://my.clevelandclinic.org/disorders/sepsis/hic_sepsis.aspx Cannon JG (2000). "Inflammatory Cytokines in Nonpathological States". News Physiol Sci. Cannon JG (2000). "Inflammatory Cytokines in Nonpathological States". News Physiol Sci. 1515: :

298-303 298-303 Kabay B, Kocaefe C, Baykal A, et al. (2007). "Interleukin-10 gene transfer: prevention of multiple Kabay B, Kocaefe C, Baykal A, et al. (2007). "Interleukin-10 gene transfer: prevention of multiple

organ injury in a murine cecal ligation and puncture model of sepsis". World J Surg organ injury in a murine cecal ligation and puncture model of sepsis". World J Surg 3131 Janeway CA, et al., ed (2005). Immunobiology. The immune system in Health and Disease (6th Janeway CA, et al., ed (2005). Immunobiology. The immune system in Health and Disease (6th

ed.). New York: Taylor & Francis Group; Garland Science ed.). New York: Taylor & Francis Group; Garland Science Lucas AD, Greaves DR (November 2001). "Atherosclerosis: role of chemokines and Lucas AD, Greaves DR (November 2001). "Atherosclerosis: role of chemokines and

macrophages". Expert Rev Mol Med macrophages". Expert Rev Mol Med 33 (25): 1–18. (25): 1–18. Dellinger RP, Levy MM, Carlet JM, et al., for the International Surviving Sepsis Campaign Dellinger RP, Levy MM, Carlet JM, et al., for the International Surviving Sepsis Campaign

Guidelines Committee. (2008). Guidelines Committee. (2008). McKenna M (December 2008). "Controversy swirls around early goal-directed therapy in sepsis: McKenna M (December 2008). "Controversy swirls around early goal-directed therapy in sepsis:

pioneer defends ground- breaking approach to deadly disease". pioneer defends ground- breaking approach to deadly disease". Ann Emerg MedAnn Emerg Med 5252 (6): 651–4 (6): 651–4 Carr R, Brocklehurst P, Doré CJ, Modi N (January 2009). "Granulocyte-macrophage colony Carr R, Brocklehurst P, Doré CJ, Modi N (January 2009). "Granulocyte-macrophage colony

stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial" randomised controlled trial"